Decreased AT III activity has been associated with clinical hypercoagulability in dogs and humans and is thought to be an important contributing factor to the development of a hypercoagulable state in dogs, along with protein-losing enteropathy and nephrotic syndrome [27,28,29]. This evidence concerns the gene SERPINC1 and Protein-losing enteropathy.